genedrive plc Annual Report 2017 genedrive plc  Annual Report Decentralising   molecular diagnostics 17 genedrive plc Annual Report 2017 Page Title at start: Content Section at start: genedrive plc Annual Report 2017 genedrive plc is focused  on decentralising  molecular diagnostics,  concentrating on  applications where our  technology will provide  sustainable growth. Strategic Report Highlights 1 Our Focus 2 Chairman’s Statement 4 Chief Executive’s Review 6 Market Opportunity 8 Financial Review 12 Key Performance Indicators 13 Principal Risks And Uncertainties 15 Governance Board of Directors 16 Directors’ Report 18 Directors’ Remuneration Report 21 Corporate Governance Report 25 Financial Statements Independent Auditor’s Report (Group) 27 Consolidated Statement of Profit or Loss   and Comprehensive Income 32 Consolidated Balance Sheet 33 Consolidated Statement of Changes in Equity 34 Consolidated Cash Flow Statement 35 Notes to the Financial Statements 36 Independent Auditors’ Report (Company) 61 Company Balance Sheet 65 Company Statement of Changes in Equity 66 Company Statement of Cash Flows 67 Notes to the Company Financial Statements 68 Directors, Secretary and Advisers 71 WHAT WE DO Introduction and highlights Page Title at start: Content Section at start: Financial Statements Governance Strategic Report   genedrive plc Annual Report 2017  1 Operational Highlights  ● Proprietary Genedrive® Hepatitis C (HCV) test  submitted for CE marking   ● Continued positive progress with the US DoD  biohazard identifier programme, including  extension of programme into next phase  ● Successful field trials of Genedrive® aquaculture  testing programme, performed in collaboration  with the Centre for Environment, Fisheries and  Aquaculture Science (Cefas)  ● Disappointing uptake of MTB/RIF assay in India, in  part owing to sample preparation problems  specific to MTB and commercial issues  ● Name change from Epistem Holdings Plc to  genedrive plc and £6m raised from July 2016  placing - strategic focus on  molecular diagnostics  business opportunities Financial Highlights Post Year End  ● CE marking obtained for Genedrive® HCV ID kit  ● Entered into a distribution agreement with Sysmex  Europe for Genedrive® HCV ID kit in the EMEA  region with an initial focus on Africa  ● Entered into the next stage of the US DoD  biohazard programme, worth approximately $1.4m  in development income and a further $0.5m in  product sales all expected to be recognised in the  current financial year  ● £0.6m conditional grant offer from Innovate UK to  fund centrifuge free plasma separation device £5.8m +13.7% Revenue and   other income (2016: £5.1m) £3.2m +3.2% Service Income  (2016: £3.1m)    ● Turnover of £5.8m, up 13.7% (2016: £5.1m)  ● Strong growth in Genedrive® development income  to £2.6m (2016: £2.0m) principally driven by the US  Department of Defense (DoD) biohazard  programme  ● Moderate increase in Service income to £3.2m  (2016: £3.1m)  ● Trading loss improvement to £4.9m (2016: £5.4m)  despite increased Research & Development and  Administrative costs  ● Cash at 30 June 2017 of £5.1m (2016: £1.1m)   post £6.0m equity fund raising in July 2016;   30 September 2017 cash of £4.2 (unaudited)  ● Loss for the year £6.4m, up 8.5% from £5.9m in   the prior year reflecting an impairment charge and  tax credit £2.6m +30.0% Development   Income  (2016: £2.0m) £5.1m +363.6% Cash  (2016: £1.1m)  Page Title at start: Content Section at start: Highlights Strategic Report genedrive plc Annual Report 2017 2 Easy to use single   button operation with simple software. SIMPLE VERSATILE FAST OUR FOCUS Changing the way molecular diagnostics   and personalised medicine are delivered Genedrive ®  is an innovative,  easy to use platform that  brings molecular diagnostics  to decentralised laboratories. Overview Genedrive® is a patented small polymerase chain reaction  (PCR) platform which enables rapid nucleic acid amplification  and detection from various sample types, including plasma,  sputum and buccal swabs. With minimal hands on time and  single button operation, it provides diagnostic results, without  the need for specialist knowledge or data interpretation. With  no manual calibration or maintenance required, Genedrive® is  ideal for low throughput, decentralised laboratories. Results available in as   little as 50 minutes. Various sample types  including plasma, sputum or buccal swab. Page Title at start: Content Section at start: Our Focus Financial Statements Governance Strategic Report   genedrive plc Annual Report 2017  3 LOW  COST PORTABLE Decentralised testing  supported by mains power or UPS battery pack. Affordable platform  facilitates testing in low throughput settings..